Why the study?
While heparin has long been the primary anticoagulant for ECMO support, bivalirudin has emerged as an alternative, warranting a summary of comparative studies.
Does bivalirudin reduce bleeding and thrombotic complications compared to unfractionated heparin in patients requiring ECMO support?
Population
Patients undergoing ECMO support across 16 comparative studies and 8 meta-analysis and review articles
Comparison
Heparin vs bivalirudin
Design
Systematic review based on PRISMA guidelines
Authors
Loading...
Supports bivalirudin as alternative in ECMO; extends evidence on stable anticoagulation and lower transfusion needs.
Does bivalirudin reduce bleeding and thrombotic complications compared to unfractionated heparin in patients requiring ECMO support?
Bivalirudin is a safe and potentially beneficial alternative to unfractionated heparin for ECMO anticoagulation, offering more stable anticoagulation and potentially decreasing circuit clotting and major bleeding complications.
Navaei et al. (2023) studied this question.